Quarterly ResultOct 30, 2026, 04:51 PM
Ligand Pharmaceuticals Reports Q3 Net Loss of $28.5M
AI Summary
Ligand Pharmaceuticals Inc. reported a net loss of $28.5 million for the third quarter of 2026, a significant shift from a net income of $117.3 million in the same period of 2025. Revenue from intangible royalty assets saw an increase to $47.4 million, while income from financial royalty assets also rose to $22.9 million. However, total revenues and income decreased to $78.7 million from $115.5 million year-over-year. The company's balance sheet shows substantial growth in both total assets to $2.24 billion and total liabilities to $1.28 billion by the end of the third quarter of 2026.
Key Highlights
- Revenue from intangible royalty assets increased to $47.4M in Q3 2026 from $40.2M in Q3 2025.
- Income from financial royalty assets increased to $22.9M in Q3 2026 from $6.4M in Q3 2025.
- Total revenues and income decreased to $78.7M in Q3 2026 from $115.5M in Q3 2025.
- Net loss for Q3 2026 was $28.5M, compared to net income of $117.3M in Q3 2025.
- Basic net loss per share was $1.43 in Q3 2026, compared to basic net income per share of $5.99 in Q3 2025.
- Total assets grew to $2.24B as of Sep 30, 2026, from $1.56B as of Dec 31, 2025.
- Total liabilities grew to $1.28B as of Sep 30, 2026, from $0.54B as of Dec 31, 2025.
Price Impact
More from LGND